Skip to main content
. 2024 May 16;120(12):1400–1410. doi: 10.1093/cvr/cvae109

Graphical Abstract.

Graphical Abstract

Long-term efficacy and safety of inclisiran. ADA, anti-drug antibody; ASCVD, atherosclerotic cardiovascular disease; EOS, end-of-study; LDL-C, low-density lipoprotein cholesterol; PY, patient-years; TEAE, treatment-emergent adverse event.